Muterol20 mg

Muterol is indicated for the long-term maintenance treatment of reversible airway obstruction associated with asthma and chronic obstructive pulmonary disease (COPD), particularly for the control of nocturnal symptoms and early-morning bronchoconstriction.

• Established/guideline-supported use: Regular maintenance bronchodilation in persistent asthma and in COPD, given once daily (usually at bedtime) to provide sustained bronchodilation over approximately 24 hours.
• Combination requirement (asthma): As a long-acting beta-2 agonist (LABA), Muterol should not be used as monotherapy in asthma. It must be used together with an appropriate inhaled corticosteroid (or other anti-inflammatory maintenance therapy), never as a substitute for it.
• Not indicated for: Relief of acute bronchospasm or acute asthma attacks. Muterol has a slow onset of action and is not a rescue medicine; a fast-acting short-acting beta agonist (SABA) inhaler should be used for acute symptoms.

Each tablet contains Bambuterol Hydrochloride as the active ingredient, commonly available in strengths such as 10 mg and 20 mg, along with pharmaceutically acceptable excipients (e.g., lactose, microcrystalline cellulose, magnesium stearate) used for tablet formulation.

Muterol is an orally active, long-acting beta-2 adrenergic agonist (LABA) that acts as a prodrug of terbutaline. After absorption, it is slowly and continuously converted in the body (mainly via plasma and hepatic esterases) to terbutaline, its active bronchodilator metabolite. This slow, sustained conversion gives Muterol a long duration of action, allowing once-daily dosing for maintenance bronchodilation in asthma and COPD.

Because of its slow onset, Muterol is intended for regular scheduled use to prevent symptoms, not for rapid relief of an acute asthma or COPD flare-up.

Long-acting Beta-2 Adrenergic Agonist (LABA); Bronchodilator (anti-asthmatic / anti-COPD agent). Muterol belongs to this class as a prodrug form.

Bambuterol Hydrochloride is a prodrug that is hydrolyzed slowly and continuously, principally by plasma cholinesterase (butyrylcholinesterase) and hepatic esterases, to its active metabolite terbutaline. Terbutaline is a selective beta-2 adrenergic receptor agonist.

Stimulation of beta-2 receptors on bronchial smooth muscle activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP). This relaxes bronchial smooth muscle, producing bronchodilation and relief of airway obstruction. Because Bambuterol Hydrochloride is converted gradually rather than absorbed as an already-active drug, plasma terbutaline concentrations rise slowly and remain sustained, giving a long duration of bronchodilator effect (approximately 24 hours) suited to once-daily, typically bedtime, dosing.

A pharmacologically relevant property of Bambuterol Hydrochloride is that it inhibits plasma cholinesterase activity; this is clinically important because it can prolong the neuromuscular blocking effect of suxamethonium (succinylcholine) if surgery is required (see Interactions).

Take Muterol tablets by mouth, swallowed whole with a glass of water. It is usually taken once daily at bedtime to provide bronchodilation through the night and early morning. It may be taken with or without food. Do not crush or chew unless directed by a physician or pharmacist. Take it regularly, even when feeling well, as it is a maintenance (preventer-supporting) medicine, not a rescue treatment.

• Beta-blockers (especially non-selective, e.g., propranolol): May antagonize the bronchodilator effect of Muterol and precipitate bronchospasm; concurrent use should generally be avoided in patients with asthma/COPD.
• Other sympathomimetic agents: Concomitant use with other beta-agonists or sympathomimetics may increase the risk of cardiovascular side effects (tachycardia, arrhythmia) with Muterol.
• Xanthine derivatives (e.g., theophylline), corticosteroids, and diuretics (loop or thiazide): May increase the risk of hypokalemia when used together with Muterol; serum potassium monitoring is advised, especially in severe asthma exacerbations.
• Suxamethonium (succinylcholine): Muterol inhibits plasma cholinesterase and can significantly prolong the neuromuscular blocking (paralytic) effect of suxamethonium. Anesthesiologists/surgeons must be informed if a patient is taking Muterol before any surgery requiring muscle relaxants; enzyme activity may take up to about two weeks after stopping Muterol to normalize.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: May potentiate the cardiovascular effects of Muterol; use with caution.
• Digoxin: Hypokalemia associated with beta-agonist use, including Muterol, may increase the risk of digoxin-related cardiac arrhythmias.

Side effects of Muterol are generally dose-related and reflect beta-2 adrenergic stimulation.

• Common: Fine tremor (particularly of the hands), headache, nervousness/restlessness, palpitations, muscle cramps.
• Less common: Tachycardia, peripheral vasodilation, sleep disturbance, nausea, hypokalemia (low blood potassium — see Precautions).
• Rare: Hypersensitivity reactions (rash, angioedema, bronchospasm), cardiac arrhythmias (including atrial fibrillation), and paradoxical bronchospasm.

Patients should seek medical advice if side effects are severe or persistent.

Pregnancy: There is limited controlled human data on the use of Muterol in pregnancy. Muterol should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under the direction of a physician. Particular caution is advised in late pregnancy/around labor, since beta-2 agonists such as the active metabolite of Muterol can theoretically relax the uterus and inhibit contractions.

Lactation: The active metabolite of Muterol (terbutaline) passes into breast milk in small amounts. Muterol should be used during breastfeeding only if considered necessary by a physician, with the infant monitored for possible effects (irritability, tremor).

Always consult a physician before using Muterol during pregnancy or while breastfeeding.

• Not a rescue medicine: Muterol has a slow onset of action and long duration; it must not be used to treat acute bronchospasm or an acute asthma attack. A short-acting bronchodilator should be available for such episodes.
• LABA monotherapy warning (asthma): As a long-acting beta-2 agonist, Muterol should not be used alone as the sole maintenance treatment for asthma. Regular use of a LABA without a concomitant inhaled corticosteroid/anti-inflammatory therapy has been associated with an increased risk of severe asthma exacerbations and asthma-related death; Muterol should always be combined with appropriate anti-inflammatory maintenance therapy in asthma, as directed by a physician.
• Cardiovascular disease: Use Muterol with caution in patients with ischemic heart disease, arrhythmias, hypertension, or other cardiovascular disorders, as beta-2 stimulation can cause tachycardia and, rarely, arrhythmias.
• Hyperthyroidism: Use with caution, as beta-agonist effects may be exaggerated.
• Diabetes mellitus: Muterol may affect blood glucose control; monitor glucose levels, particularly at higher doses.
• Hypokalemia risk: Muterol can lower serum potassium. This risk is increased with concomitant diuretics, xanthine derivatives, or corticosteroids, and during severe asthma exacerbations (where hypoxia can worsen the effect). Serum potassium should be monitored in at-risk patients.
• Renal/hepatic impairment: Dose reduction is required in renal impairment; Muterol is contraindicated in severe hepatic impairment (see Contraindications).

Overdose of Muterol may cause exaggerated beta-2 adrenergic effects, including tachycardia, palpitations, tremor, headache, nervousness, hypokalemia, hyperglycemia, and, rarely, arrhythmias or seizures.

If an overdose of Muterol is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is generally supportive and should be provided in a medical setting (e.g., cardiac monitoring, correction of electrolyte disturbances); do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: May be more sensitive to the cardiovascular side effects of Muterol (tachycardia, arrhythmia); use with caution and monitor accordingly.
• Renal impairment: A reduced starting dose of Muterol is advised because the active metabolite is eliminated renally; monitor for accumulation.
• Hepatic impairment: Muterol is contraindicated in severe hepatic impairment; use with caution and physician oversight in mild-to-moderate impairment.
• Pediatric patients: Muterol may be used from 2 years of age at appropriate reduced doses (see Dosage). Safety and efficacy below 2 years have not been established.

Muterol is intended for long-term, regular maintenance use in asthma and COPD, continued for as long as the physician determines ongoing bronchodilator therapy is needed to control symptoms. Treatment should be reviewed periodically by the prescribing physician, who may adjust the dose or therapy based on symptom control; Muterol should not be stopped abruptly without medical advice if it is part of an ongoing maintenance regimen, and asthma control should always be reassessed together with concurrent anti-inflammatory therapy.

Long-acting Beta-2 Adrenergic Agonists (LABA); Bronchodilators; Anti-asthmatic and anti-COPD agents

Bambuterol Hydrochloride is a prodrug that is slowly hydrolyzed by plasma and hepatic esterases to terbutaline, a selective beta-2 adrenergic agonist. Terbutaline stimulates beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and raising intracellular cAMP, which relaxes airway smooth muscle and produces sustained bronchodilation lasting approximately 24 hours after a single dose of Bambuterol Hydrochloride.

Muterol can be used in children from 2 years of age for maintenance treatment of asthma, at doses lower than the adult dose (see Dosage and Administration). Because of its slow, sustained onset, Muterol is not suitable for relieving acute symptoms in children and must be combined with appropriate anti-inflammatory (e.g., inhaled corticosteroid) therapy rather than used alone. Safety and efficacy of Muterol in children below 2 years of age have not been established, and it is not recommended in this age group. Children receiving Muterol should be monitored for beta-agonist side effects such as tremor, palpitations, and restlessness.